Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.50 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 7/20 | 0.49 |
| ▸ | CTSL | P07711 | 4/20 | 0.49 |
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
| ▸ | BCHE | P06276 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.48 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.48 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 7/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29360411 | 0.94 | CTSS (0.54) | PSMB1CTSSCTSLCTSBBCHE | |
| SCHEMBL29361326 | 0.91 | SMN1; SMN2 (0.53) | CTSSCTSLCTSBBCHEACHE | |
| SCHEMBL29357797 | 0.90 | NMBR (0.52) | CTSSCTSLCTSBBCHEACHE | |
| SCHEMBL29361054 | 0.89 | SIRT5 (0.55) | — | |
| SCHEMBL7904398 | 0.87 | CTSK (0.51) | PSMB5CTSSCTSLCTSBBCHE | |
| SCHEMBL30902868 | 0.87 | CTSK (0.51) | PSMB5CTSSCTSLCTSBBCHE | |
| SCHEMBL22494015 | 0.87 | CTSK (0.50) | CTSSCTSLCTSBBCHEACHE | |
| SCHEMBL22494016 | 0.87 | CTSK (0.50) | CTSSCTSLCTSBBCHEACHE | |
| SCHEMBL20740990 | 0.87 | CASP3 (0.54) | PSMB5CTSSCTSLCTSBCTSK | |
| SCHEMBL19015971 | 0.87 | CASP3 (0.54) | PSMB5CTSSCTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289848-A1 | PEPTIDOMIMETIC INHIBITORS OF B-CATENIN/TCF PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2025-09-18 | — | — | US | disclosed |
| US-12269899-B2 | Peptidomimetic inhibitors of β-catenin/Tcf protein-protein interaction | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20220024977-A1 | PEPTIDOMIMETIC INHIBITORS OF B-CATENIN/TCF PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289848-A1 | PEPTIDOMIMETIC INHIBITORS OF B-CATENIN/TCF PROTEIN-PROTEIN INTERACTION | CTNNB1, CTNNBL1, CTNND1 | PSMB8 2067/4885PSMB5 2385/4885PSMB1 1277/4885 |
| US-12269899-B2 | Peptidomimetic inhibitors of β-catenin/Tcf protein-protein interaction | CTNNB1, CTNNBL1, CTNND1 | PSMB8 1935/4885PSMB5 2504/4885PSMB1 1201/4885 |
| US-20220024977-A1 | PEPTIDOMIMETIC INHIBITORS OF B-CATENIN/TCF PROTEIN-PROTEIN INTERACTION | CTNNB1, CTNNBL1, CTNND1 | PSMB8 2067/4885PSMB5 2385/4885PSMB1 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.